Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer

Journal of Interferon and Cytokine Research

Volumn 36, Issue 1, 2016, Pages 62-73

  Cohen, Courtney A ^a   Shea, Amanda A ^b   Heffron, C Lynn ^a   Schmelz, Eva M ^b   Roberts, Paul C ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR7; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; DECTIN 1; INTERLEUKIN 12; MITOMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; ALPHA CHEMOKINE; CCL2 PROTEIN, MOUSE; CCL7 PROTEIN, MOUSE; CXCL1 PROTEIN, MOUSE; CXCL2 PROTEIN, MOUSE; CXCL3 PROTEIN, MOUSE;

ACCESSORY CELL; ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CELL ENGINEERING; CELL INTERACTION; CELL PROTECTION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION PROFILING; IMMUNOGENICITY; IMMUNOMODULATION; MACROPHAGE; METASTASIS POTENTIAL; MOUSE; NEUTROPHIL; NONHUMAN; OVARY CANCER; PERITONEAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; TH1 CELL; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; INTRAABDOMINAL FAT; NEUTROPHIL CHEMOTAXIS; OMENTUM; OVARY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; SECONDARY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; CHEMOKINE CCL2; CHEMOKINE CCL7; CHEMOKINE CXCL1; CHEMOKINE CXCL2; CHEMOKINES, CXC; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; INTERLEUKIN-12; INTRA-ABDOMINAL FAT; MACROPHAGES; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NEUTROPHILS; OMENTUM; OVARIAN NEOPLASMS; OVARY; PERITONEAL NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84954412236     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2015.0049     Document Type: Article

References (49)

1. Allen JW, Cardall S, Kittijarukhajorn M, Siegel CL. 2012. Incidence of ovarian maldescent in women with mullerian duct anomalies: evaluation by MRI. AJR Am J Roentgenol 198(4):W381-W385.
2. Anderson AS, Roberts PC, Frisard MI, Hulver MW, Schmelz EM. 2014. Ovarian tumor-initiating cells display a flexible metabolism. Exp Cell Res 328(1):44-57.
3. Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE. 2006. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res 12(20 Pt 1): 6056-6063.
4. Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. 2010. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 17(3):360-369.
5. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3(3):409-417.
6. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G. 1998. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4(1):75-85.
7. Cohen CA, Shea AA, Heffron CL, Schmelz EM, Roberts PC. 2013a. Intra-abdominal fat depots represent distinct immunomodulatory microenvironments: A murine model. PLoS One 8(6):e66477.
8. Cohen CA, Shea AA, Heffron CL, Schmelz EM, Roberts PC. 2013b. The parity-associated microenvironmental niche in the omental fat band is refractory to ovarian cancer metastasis. Cancer Prev Res (Phila) 6(11):1182-1193.
9. Colombo MP, Trinchieri G. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13(2):155-168.
10. Creekmore AL, Silkworth WT, Cimini D, Jensen RV, Roberts PC, Schmelz EM. 2011. Changes in gene expression and cellular architecture in an ovarian cancer progression model. PLoS One 6(3):e17676.
11. Curtsinger JM, Lins DC, Mescher MF. 2003. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197(9):1141-1151.
12. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. 2007. Interleukin-12: biological properties and clinical application. Clin Cancer Res 13(16): 4677-4685.
13. Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. 2006. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 169(5):1739-1752.
14. Ghosn EE, Cassado AA, Govoni GR, Fukuhara T, Yang Y, Monack DM, Bortoluci KR, Almeida SR, Herzenberg LA, Herzenberg LA. 2010. Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci U S A 107(6):2568-2573.
15. Gray KS, Collins CM, Speck SH. 2012. Characterization of omental immune aggregates during establishment of a latent gammaherpesvirus infection. PLoS One 7(8):e43196.
16. Humpf HU, Schmelz EM, Meredith FI, Vesper H, Vales TR, Wang E, Menaldino DS, Liotta DC, Merrill AH, Jr. 1998. Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor. J Biol Chem 273(30):19060-19064.
17. Hunn J, Rodriguez GC. 2012. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 55(1): 3-23.
18. Jana M, Dasgupta S, Saha RN, Liu X, Pahan K. 2003. Induction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages. J Neurochem 86(2):519-528.
19. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. 1999. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today 20(12):561-567.
20. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP. 2011. IL-12 triggers a programmatic change in dysfunctional myeloidderived cells within mouse tumors. J Clin Invest 121(12): 4746-4757.
21. Khan T, Heffron CL, High KP, Roberts PC. 2014. Tailored vaccines targeting the elderly using whole inactivated influenza vaccines bearing cytokine immunomodulators. J Interferon Cytokine Res 34(2):129-139.
22. Krishnan V, Stadick N, Clark R, Bainer R, Veneris JT, Khan S, Drew A, Rinker-Schaeffer C. 2012. Using MKK4's metastasis suppressor function to identify and dissect cancer cellmicroenvironment interactions during metastatic colonization. Cancer Metastasis Rev 31(3-4):605-613.
23. Krist LF, Kerremans M, Broekhuis-Fluitsma DM, Eestermans IL, Meyer S, Beelen RH. 1998. Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother 47(4):205-212.
24. Krist LF, Kerremans M, Koenen H, Blijleven N, Eestermans IL, Calame W, Meyer S, Beelen RH. 1995. Novel isolation and purification method permitting functional cytotoxicity studies of macrophages from milky spots in the greater omentum. J Immunol Methods 184(2):253-261.
25. Lasek W, Zagozdzon R, Jakobisiak M. 2014. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 63(5):419-435.
26. Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS. 2007. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5:66.
27. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS. 2002. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8(12):3686-3695.
28. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90(7):2541-2548.
29. Lim HY, Ju HY, Chung HY, Kim YS. 2010. Antitumor effects of a tumor cell vaccine expressing a membranebound form of the IL-12 p35 subunit. Cancer Biol Ther 10(4):336-343.
30. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YC, Hakimi J. 1995. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154(1):116-127.
31. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A. 2000. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 60(13):3559-3568.
32. Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM. 2001. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 21(4):257-263.
33. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA. 2010. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70(14):5728-5739.
34. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, et al. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153(4):1697-1706.
35. Pan WY, Lo CH, Chen CC, Wu PY, Roffler SR, Shyue SK, Tao MH. 2012. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol Ther 20(5):927-937.
36. Rangel-Moreno J, Moyron-Quiroz JE, Carragher DM, Kusser K, Hartson L, Moquin A, Randall TD. 2009. Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immunity 30(5):731-743.
37. Roberts PC, Mottillo EP, Baxa AC, Heng HH, Doyon-Reale N, Gregoire L, Lancaster WD, Rabah R, Schmelz EM. 2005. Sequential molecular and cellular events during neoplastic progression: A mouse syngeneic ovarian cancer model. Neoplasia 7(10):944-956.
38. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC. 1999. Interleukin-12 therapy of cutaneous Tcell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94(3):902-908.
39. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101-1108.
40. Sorensen EW, Gerber SA, Sedlacek AL, Rybalko VY, Chan WM, Lord EM. 2009. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res 45(2-3):185-194.
41. Tahara H, Zeh HJ, 3rd, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54(1):182-189.
42. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, 3rd, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154(12):6466-6474.
43. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3(2): 133-146.
44. Watkins SK, Egilmez NK, Suttles J, Stout RD. 2007. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 178(3):1357-1362.
45. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE. 2011. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 121(5): 1969-1973.
46. Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. 2007. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother 30(1):75-82.
47. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM. 2012. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122(4):1271-1282.
48. Yoo JK, Cho JH, Lee SW, Sung YC. 2002. IL-12 provides proliferation and survival signals to murine CD4+ T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 169(7):3637-3643.
49. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA. 2011. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19(4):751-759.